ES2042529T3 - Un procedimiento para preparar una composicion terapeutica combinada de un eliminador de radicales libres o inhibidor metabolico y una proteina biologicamente activa. - Google Patents
Un procedimiento para preparar una composicion terapeutica combinada de un eliminador de radicales libres o inhibidor metabolico y una proteina biologicamente activa.Info
- Publication number
- ES2042529T3 ES2042529T3 ES87117149T ES87117149T ES2042529T3 ES 2042529 T3 ES2042529 T3 ES 2042529T3 ES 87117149 T ES87117149 T ES 87117149T ES 87117149 T ES87117149 T ES 87117149T ES 2042529 T3 ES2042529 T3 ES 2042529T3
- Authority
- ES
- Spain
- Prior art keywords
- preparing
- removal
- procedure
- biologically active
- free radicals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002503 metabolic effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 101710112752 Cytotoxin Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 2
- 239000002619 cytotoxin Substances 0.000 abstract 2
- 239000003607 modifier Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- LAXXPOJCFVMVAX-UHFFFAOYSA-N 2-azaniumyl-4-butylsulfanylbutanoate Chemical compound CCCCSCCC(N)C(O)=O LAXXPOJCFVMVAX-UHFFFAOYSA-N 0.000 abstract 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010029333 Neurosis Diseases 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical group N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- ROSJKFFLIXTTAW-UHFFFAOYSA-N n,n-bis(2-chloroethyl)aniline Chemical compound ClCCN(CCCl)C1=CC=CC=C1 ROSJKFFLIXTTAW-UHFFFAOYSA-N 0.000 abstract 1
- 208000015238 neurotic disease Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
EL DAÑO DE CELULAS, TEJIDOS Y OTRAS PARTES DE UN HUESPED MAMIFERO PUEDE SER TRATADO CON UNA PREPARACION FARMACEUTICA PRODUCIDA USANDO UNA LINFOQUINA O CITOTOXINA EN COMBINACION CON UN MODIFICADOR BIOLOGICO POR LO MENOS, QUE PUEDE SER UN CAPTADOR DE RADICALES LIBRES O UN INHIBIDOR METABOLICO. LA LINFOQUINA O CITOTOXINA ES PREFERIBLEMENTE EL FACTOR DE NEUROSIS DE TUMORES Y EL MODIFICADOR BIOLOGICO ES PREFERENTEMENTE ACIDO URICO, BUTIONINA SULFOXIMINA, VITAMINA C, ASPIRINA O ACIDO NORHIDROGUAYARETICO. DICHA PREPARACION FARMACEUTICA PUEDE SER EMPLEADA PARA TRATAR, POR EJEMPLO, CANCER, ENFERMEDADES INFECCIOSAS Y LOS DAÑOS CAUSADOS POR TERAPIA DE RADIACIONES; ALTA TENSION DE OXIGENO Y QUINOTERAPIA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93347586A | 1986-11-21 | 1986-11-21 | |
| US11364387A | 1987-10-26 | 1987-10-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2042529T3 true ES2042529T3 (es) | 1993-12-16 |
| ES2042529T4 ES2042529T4 (es) | 1996-07-16 |
Family
ID=26811304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES87117149T Expired - Lifetime ES2042529T4 (es) | 1986-11-21 | 1987-11-20 | Un procedimiento para preparar una composicion terapeutica combinada de un eliminador de radicales libres o inhibidor metabolico y una proteina biologicamente activa. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0269017B1 (es) |
| CA (1) | CA1321349C (es) |
| DE (1) | DE3780770T2 (es) |
| ES (1) | ES2042529T4 (es) |
| GR (1) | GR3005314T3 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5296500A (en) * | 1991-08-30 | 1994-03-22 | The Procter & Gamble Company | Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy |
| US5523077A (en) * | 1992-02-06 | 1996-06-04 | Yale University | Composition and method for whitening skin |
| GB9226729D0 (en) * | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
| DE69330285D1 (de) * | 1993-03-10 | 2001-07-05 | Univ Yale New Haven | Mittel und verfahren zur bleichung der haut |
| US5686436A (en) | 1993-05-13 | 1997-11-11 | Hiv Diagnostics, Inc. | Multi-faceted method to repress reproduction of latent viruses in humans and animals |
| EP0750496A1 (en) * | 1994-03-14 | 1997-01-02 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents |
| US5451405A (en) * | 1994-04-25 | 1995-09-19 | Chesebrough-Pond's Usa Co. | Skin treatment composition |
| IL141627A0 (en) * | 1998-08-24 | 2002-03-10 | Maxim Pharm Inc | Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents |
| EP3678739B1 (en) | 2017-09-07 | 2024-03-13 | The Children's Hospital of Philadelphia | Compositions and methods for treatment of hereditary cystatin c amyloid angiopathy ( hccaa) and other neurodegenerative disorders associated with aberrant amyloid deposits |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1526205A (en) * | 1974-11-07 | 1978-09-27 | Searle & Co | Treatment of interferon-like material |
| EP0177342A3 (en) * | 1984-10-04 | 1987-12-02 | Genentech, Inc. | Oral formulation of therapeutic proteins |
-
1987
- 1987-11-12 CA CA000551719A patent/CA1321349C/en not_active Expired - Fee Related
- 1987-11-20 EP EP87117149A patent/EP0269017B1/en not_active Expired - Lifetime
- 1987-11-20 ES ES87117149T patent/ES2042529T4/es not_active Expired - Lifetime
- 1987-11-20 DE DE8787117149T patent/DE3780770T2/de not_active Expired - Fee Related
-
1992
- 1992-07-30 GR GR920400697T patent/GR3005314T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0269017A2 (en) | 1988-06-01 |
| DE3780770T2 (de) | 1993-02-25 |
| DE3780770D1 (de) | 1992-09-03 |
| EP0269017A3 (en) | 1989-06-21 |
| ES2042529T4 (es) | 1996-07-16 |
| EP0269017B1 (en) | 1992-07-29 |
| GR3005314T3 (es) | 1993-05-24 |
| CA1321349C (en) | 1993-08-17 |
| JPS63190831A (ja) | 1988-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2080837T3 (es) | Tratamiento de estados y enfermedades. | |
| ES2116986T3 (es) | Composiciones de metal-peptidos y metodos cosmeticos para estimular el crecimiento del cabello. | |
| LV10180A (lv) | Farmaceitiska kompozicija | |
| ES2167377T3 (es) | Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos. | |
| ES2136618T3 (es) | Cicatrizacion de heridas. | |
| ES8103162A1 (es) | Un procedimiento para la preparacion de interferon tipo ii. | |
| AR003427A1 (es) | Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas. | |
| Grimes | Psoralen photochemotherapy for vitiligo | |
| ATE111735T1 (de) | Verwendung des wirkstoffs azelastin und glycerinethern zur bekämpfung von psoriasis- erkrankungen. | |
| AR006401A1 (es) | Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos. | |
| ES2033021T3 (es) | Agente con efecto destructivo a tumores malignos, procedimiento para su obtencion y preparacion para la aplicacion en la terapia de enfermos de cancer. | |
| ATE55695T1 (de) | Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien. | |
| ES2051675T3 (es) | Inhibidores de protorfirinogeno y su uso en composiciones para detectar y tratar tumores. | |
| ES2063767T3 (es) | Esteres aromaticos policiclicos de antibioticos macrolidicos y lincosamidicos, su procedimiento de preparacion y composiciones farmaceuticas y cosmeticas que los contienen. | |
| DE59409394D1 (de) | Therapeutisches system zur behandlung der psoriasis | |
| ES2150902T3 (es) | Procedimientos para potenciar la cicatrizacion de heridas y la reparacion de tejidos. | |
| ATE253117T1 (de) | Adenovirus e4 proteine für induktion von zelltod | |
| ATE352306T1 (de) | Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen | |
| DE69111974D1 (de) | Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum. | |
| DE69133077D1 (de) | Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung | |
| AR010924A1 (es) | Azapeptidos ciclicos, sus enantiomeros y diastereomeros, un procedimiento para su preparacion, su empleo para preparar un medicamento, las preparacionesfarmaceuticas que los contienen y un procedimiento para obtener estas preparaciones farmaceuticas. | |
| DE69110615D1 (de) | Verwendung von Aminosäuren zum Schutz von ischemischem Herzgewebe und dessen metabolischer Wiederherstellung. | |
| SE8102161L (sv) | "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra | |
| ES2110057T3 (es) | Composicion medicinal que contiene tcf-ii. | |
| ATE141510T1 (de) | Arzneimittel enthaltend cd14 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 0269017 Country of ref document: ES |